<p>辉瑞公司正在加大对蓬勃发展的减肥药市场的投入，首席执行官阿尔伯特·布尔拉（Albert Bourla）宣称，公司将成为一个&#34;强大的竞争者&#34;，并已达成一项价值 100 亿美元的交易，收购肥胖药物开发公司 Metsera。</p>
<p>布尔拉在&#34;Mornings with Maria&#34;节目中表示：&#34;辉瑞一旦出手，就会大举出击，正如我们在 COVID 期间、在立普妥（Lipitor）、伟哥（Viagra）以及我们发明并推向市场的所有药物中所做的一样，我们将在肥胖药物上也做到这一点。&#34;</p>
<p>这项交易使制药巨头能够获得仍在试验中的新减肥治疗的权利，进入一个已经被像礼来（Eli Lilly）的 Zepbound 和诺和诺德（Novo Nordisk）的 Wegovy 等流行 GLP-1 药物挤满的市场。</p>
<p>辉瑞预计将在 2028 年底之前推出其首款减肥治疗药物，这一举措可能使其能够占据布尔拉所称的&#34;巨大的&#34;市场份额，估计约为 1500 亿到 2000 亿美元。</p>
<p><strong>辉瑞在重大制药收购中以 100 亿美元赢得肥胖药物开发公司 Metsera 的竞标战</strong></p>
<p><img src="https://imageproxy.pbkrs.com/https://a57.foxnews.com/static.foxbusiness.com/foxbusiness.com/content/uploads/2025/11/931/523/glp-1-injection-in-belly-v2.jpg/query-dGw9MSZ2ZT0x?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://a57.foxnews.com/static.foxbusiness.com/foxbusiness.com/content/uploads/2025/11/931/523/glp-1-injection-in-belly-v2.jpg/query-dGw9MSZ2ZT0x"/></p>
<p>一名女性在这张未注明日期的照片中，在一个未公开的地点将 GLP-1 注射剂注入她的腹部。(iStock / iStock)</p>
<p>Metsera 的交易是在辉瑞与诺和诺德之间经过数月的反复谈判后达成的，双方都在竞标该公司。</p>
<p>布尔拉表示，辉瑞从 Metsera 收购了&#34;非常好的产品组合&#34;，并将继续在此基础上发展，以成为该领域的&#34;强大竞争者&#34;。</p>
<p>这家制药巨头拥有自己的直销平台 PfizerForAll，正与特朗普政府推动降低处方药价格的政策保持一致，协调白宫即将推出的 TrumpRx 平台，旨在让美国人更直接地获得药物，而不依赖传统的保险公司或中介。</p>
<p><strong>巴蒂亚·乌恩加尔 - 萨尔贡：特朗普如何利用同样的策略遏制大型制药公司，确保中东和平</strong></p>
<p><img src="https://imageproxy.pbkrs.com/https://a57.foxnews.com/static.foxbusiness.com/foxbusiness.com/content/uploads/2023/08/931/523/Wegovy-2.jpg/query-dGw9MSZ2ZT0x?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://a57.foxnews.com/static.foxbusiness.com/foxbusiness.com/content/uploads/2023/08/931/523/Wegovy-2.jpg/query-dGw9MSZ2ZT0x"/></p>
<p>2023 年 6 月 28 日，在丹麦哥本哈根的一家药店，诺和诺德公司的减肥药 Wegovy 的各种包装摆放在销售柜台上。近年来，GLP-1 药物因其效果而受到广泛欢迎。(Steffen Trumpf/picture alliance via Getty Images / Getty Images)</p>
<p>布尔拉表示：&#34;我认为他刚刚提到的 TrumpRx 是美国人以极低的成本获得药物的绝佳机会。&#34;</p>
<p>&#34;这将创造非常积极的势头，许多因无法承担药物费用而放弃处方的患者——现在他们将能够获得，因此我们将有更多的药物在患者手中，创造一个更健康的美国。&#34;</p>
<p>布尔拉表示，公司将把药物与 TrumpRx 计划整合，以简化药物获取的流程。</p>
<p><strong>点击这里获取福克斯商业新闻</strong></p>
<p>&#34;我们将能够拥有一个完整的网站，包含我们将纳入 TrumpRx 的 40 多种产品，&#34;他分享道。</p>
<p>&#34;它将在 12 月准备就绪，因此，当 TrumpRx 推出时，能够立即将登录该网站的用户引导到我们的网站，以便我们处理所有的物流。&#34;</p>

MTSR

辉瑞

<p>辉瑞公司已以 100 亿美元收购肥胖药物开发商 Metsera，旨在成为减肥药市场的重要参与者。首席执行官阿尔伯特·布尔拉强调了辉瑞对创新的承诺，将其与过去的成功案例如立普妥和伟哥进行比较。这项收购使辉瑞能够与流行的 GLP-1 药物竞争，并与特朗普政府降低处方药价格的倡议相一致。辉瑞计划将其产品与 TrumpRx 平台整合，以增强药物的可及性</p>

<p>Pfizer Inc. is doubling down on the booming weight-loss drug race, with CEO Albert Bourla declaring the company will be a &#34;formidable competitor&#34; after securing a $10 billion deal to acquire obesity-drug developer Metsera.</p>
<div class="lb-trans"><p>辉瑞公司正在加大对蓬勃发展的减肥药市场的投入，首席执行官阿尔伯特·布尔拉（Albert Bourla）宣称，公司将成为一个&#34;强大的竞争者&#34;，并已达成一项价值 100 亿美元的交易，收购肥胖药物开发公司 Metsera。</p>
</div><p>&#34;Pfizer, when it plays, plays big, and we will, as we did in COVID, as with Lipitor, as [with] Viagra, with all the medicines that we have invented and brought to the market, we will do the same with obesity,&#34; Bourla said Thursday on &#34;Mornings with Maria.&#34;</p>
<div class="lb-trans"><p>布尔拉在&#34;Mornings with Maria&#34;节目中表示：&#34;辉瑞一旦出手，就会大举出击，正如我们在 COVID 期间、在立普妥（Lipitor）、伟哥（Viagra）以及我们发明并推向市场的所有药物中所做的一样，我们将在肥胖药物上也做到这一点。&#34;</p>
</div><p>The deal allows the pharmaceutical giant to secure the rights to new weight-loss treatments still in trials, entering a space already crowded with popular GLP-1 drugs like Eli Lilly's Zepbound and Novo Nordisk's Wegovy.</p>
<div class="lb-trans"><p>这项交易使制药巨头能够获得仍在试验中的新减肥治疗的权利，进入一个已经被像礼来（Eli Lilly）的 Zepbound 和诺和诺德（Novo Nordisk）的 Wegovy 等流行 GLP-1 药物挤满的市场。</p>
</div><p>Pfizer expects to have its first weight-loss treatment on the market by the end of 2028, a move that could position it to capture a share of what Bourla called a &#34;huge&#34; market, estimated at approximately $150 to $200 billion.</p>
<div class="lb-trans"><p>辉瑞预计将在 2028 年底之前推出其首款减肥治疗药物，这一举措可能使其能够占据布尔拉所称的&#34;巨大的&#34;市场份额，估计约为 1500 亿到 2000 亿美元。</p>
</div><p><strong>PFIZER WINS $10B BIDDING WAR FOR OBESITY DRUG DEVELOPER METSERA IN MAJOR PHARMACEUTICAL ACQUISITION</strong></p>
<div class="lb-trans"><p><strong>辉瑞在重大制药收购中以 100 亿美元赢得肥胖药物开发公司 Metsera 的竞标战</strong></p>
</div><p><img src="https://imageproxy.pbkrs.com/https://a57.foxnews.com/static.foxbusiness.com/foxbusiness.com/content/uploads/2025/11/931/523/glp-1-injection-in-belly-v2.jpg/query-dGw9MSZ2ZT0x" alt="" original-src="https://a57.foxnews.com/static.foxbusiness.com/foxbusiness.com/content/uploads/2025/11/931/523/glp-1-injection-in-belly-v2.jpg?ve=1&amp;tl=1"/></p>
<p>A woman injects a GLP-1 injection into her stomach in this undated photo taken at an undisclosed location. (iStock / iStock)</p>
<div class="lb-trans"><p>一名女性在这张未注明日期的照片中，在一个未公开的地点将 GLP-1 注射剂注入她的腹部。(iStock / iStock)</p>
</div><p>The Metsera deal followed a months-long back-and-forth between Pfizer and Novo Nordisk, which were both bidding for the company.</p>
<div class="lb-trans"><p>Metsera 的交易是在辉瑞与诺和诺德之间经过数月的反复谈判后达成的，双方都在竞标该公司。</p>
</div><p>Bourla said Pfizer acquired a &#34;very good portfolio&#34; from Metsera, and will continue building on its own to become a &#34;formidable competitor&#34; in the space.</p>
<div class="lb-trans"><p>布尔拉表示，辉瑞从 Metsera 收购了&#34;非常好的产品组合&#34;，并将继续在此基础上发展，以成为该领域的&#34;强大竞争者&#34;。</p>
</div><p>The pharmaceutical giant, which has its own direct-to-consumer platform PfizerForAll, is aligning with the Trump administration’s push to lower prescription drug prices, coordinating on the White House’s forthcoming TrumpRx platform designed to give Americans more direct access to medications without relying on traditional insurers or middle-men.</p>
<div class="lb-trans"><p>这家制药巨头拥有自己的直销平台 PfizerForAll，正与特朗普政府推动降低处方药价格的政策保持一致，协调白宫即将推出的 TrumpRx 平台，旨在让美国人更直接地获得药物，而不依赖传统的保险公司或中介。</p>
</div><p><strong>BATYA UNGAR-SARGON: HOW TRUMP USES SAME STRATEGY TO CURB BIG PHARMA, SECURE MIDEAST PEACE</strong></p>
<div class="lb-trans"><p><strong>巴蒂亚·乌恩加尔 - 萨尔贡：特朗普如何利用同样的策略遏制大型制药公司，确保中东和平</strong></p>
</div><p><img src="https://imageproxy.pbkrs.com/https://a57.foxnews.com/static.foxbusiness.com/foxbusiness.com/content/uploads/2023/08/931/523/Wegovy-2.jpg/query-dGw9MSZ2ZT0x" alt="" original-src="https://a57.foxnews.com/static.foxbusiness.com/foxbusiness.com/content/uploads/2023/08/931/523/Wegovy-2.jpg?ve=1&amp;tl=1"/></p>
<p>Various packages of the weight-loss drug Wegovy from the pharmaceutical company Novo Nordisk lie on the sales counter in a Danish pharmacy in Kopenhagen, Denmark on June 28, 2023. GLP-1 drugs have boomed in popularity in recent years due to their abi (Steffen Trumpf/picture alliance via Getty Images / Getty Images)</p>
<div class="lb-trans"><p>2023 年 6 月 28 日，在丹麦哥本哈根的一家药店，诺和诺德公司的减肥药 Wegovy 的各种包装摆放在销售柜台上。近年来，GLP-1 药物因其效果而受到广泛欢迎。(Steffen Trumpf/picture alliance via Getty Images / Getty Images)</p>
</div><p>&#34;I think the TrumpRx that he just spoke about is a wonderful opportunity for Americans to receive medicines at a fraction of the cost,&#34; Bourla said.</p>
<div class="lb-trans"><p>布尔拉表示：&#34;我认为他刚刚提到的 TrumpRx 是美国人以极低的成本获得药物的绝佳机会。&#34;</p>
</div><p>&#34;That is going to create a very positive momentum, and a lot of patients who were abandoning their prescriptions at the pharmacy because they couldn’t afford them — now they will, so we will have more medicines in the hands of patients, and a healthier America.&#34;</p>
<div class="lb-trans"><p>&#34;这将创造非常积极的势头，许多因无法承担药物费用而放弃处方的患者——现在他们将能够获得，因此我们将有更多的药物在患者手中，创造一个更健康的美国。&#34;</p>
</div><p>Bourla said the company will integrate drugs with the TrumpRx initiative to streamline access to medications.</p>
<div class="lb-trans"><p>布尔拉表示，公司将把药物与 TrumpRx 计划整合，以简化药物获取的流程。</p>
</div><p><strong>GET FOX BUSINESS ON THE GO BY CLICKING HERE</strong></p>
<div class="lb-trans"><p><strong>点击这里获取福克斯商业新闻</strong></p>
</div><p>&#34;We will be able to have a complete website with all the 40-plus products that we are going to include in this TrumpRx,&#34; he shared.</p>
<div class="lb-trans"><p>&#34;我们将能够拥有一个完整的网站，包含我们将纳入 TrumpRx 的 40 多种产品，&#34;他分享道。</p>
</div><p>&#34;It's going to be ready by December so, when TrumpRx is launched, it will be able to send immediately those that they log into that website, to our website, so that we can take care of all of the logistics.&#34;</p>
<div class="lb-trans"><p>&#34;它将在 12 月准备就绪，因此，当 TrumpRx 推出时，能够立即将登录该网站的用户引导到我们的网站，以便我们处理所有的物流。&#34;</p>
</div>

Pfizer joins the weight-loss gold rush, vows to be a ‘formidable competitor’

- 辉瑞公司以 100 亿美元收购肥胖药物开发商 Metsera，计划进入减肥药市场。  
- CEO 阿尔伯特·布尔拉表示，辉瑞将成为该领域的 “强大竞争者”。  
- 预计辉瑞将在 2028 年底前推出首款减肥药，市场规模约为 1500 亿至 2000 亿美元。

辉瑞加入减肥热潮，誓言成为 ‘强大的竞争者’